Graft Versus Host Disease Clinical Trials

15 studies are recruiting for graft versus host disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation

   This study evaluates the factors that contribute to chronic graft-versus-host disease, which is a complication that can occur after allogeneic hematopoietic cell transplantation.

   Stage

   Not phased

   Ages

   7 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT07235501 on ClinicalTrials.gov

2. Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

   Bone marrow transplants (BMT) are one form of treatment for disorders of the blood, including leukemia. However, because the procedure is often associated with potentially life-threatening reactions, it is usually reserved for patients with serious illnesses under the age of 60 years old. One serio…

   Stage

   Not phased

   Ages

   18 to 60

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Heart, Lung, and Blood Institute (NHLBI)

   See if you can join NCT00001529 on ClinicalTrials.gov

3. Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease

   The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usual care for improving self-management and quality of life for hematopoietic stem cell transplant (HSCT) survivors living with chronic graft-v…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida

   Locations

   2 in total

   Run by

   Massachusetts General Hospital

   See if you can join NCT06910969 on ClinicalTrials.gov

4. Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia

   The goal of this clinical trial is to evaluate the safety and tolerability of injecting certain cells produced in bone marrow called mesenchymal stromal cells (MSCs) into salivary glands. The main question it aims to answer is whether injection of MSCs into salivary glands results in any improvemen…

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   University of Wisconsin, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT06392711 on ClinicalTrials.gov

5. Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

   This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after reduced…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT06996119 on ClinicalTrials.gov

6. Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

   This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) after reduced intensity conditioning. Allo…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT06815003 on ClinicalTrials.gov

7. A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

   The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   8 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07006506 on ClinicalTrials.gov

8. Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

   This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the criteria defined in our standard operation procedures (SOPs)…

   Stage

   Phase 1

   Ages

   14 to 100

   Site

   Northwell Health, New Hyde Park, New York

   Run by

   Northwell Health

   See if you can join NCT05289167 on ClinicalTrials.gov

9. A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant

   The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.

   Stage

   Phase 2

   Ages

   4 and older

   Site

   National Institute of Health (Data Collection AND Specimen Analysis), Bethesda, Maryland

   Locations

   9 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05675930 on ClinicalTrials.gov

10. Cord Blood Transplantation in Children and Young Adults With Blood Cancer

    The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.

    Stage

    Phase 2

    Ages

    Up to 26

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07566377 on ClinicalTrials.gov

11. Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

    Allogeneic hematopoietic cell transplantation (HCT) is one of the only curative intent therapies available for hematologic malignancies. HLA-matched sibling donors have historically offered the best clinical results but are unavailable for the majority of patients, while most patients do have readi…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT06008808 on ClinicalTrials.gov

12. Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

    This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "gr…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Jonathan Brammer

    See if you can join NCT07356245 on ClinicalTrials.gov

13. A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

    Patients in need of an allogeneic hematopoietic cell transplant (HCT) are at risk of developing graft-versus-host-disease (GVHD). In certain clinical situations, the optimal approach to minimize the risk of GVHD is to perform ex vivo alpha-beta T-cell depletion of the donor cells. However, the Clin…

    Stage

    Not phased

    Ages

    Up to 30

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Christopher Dvorak

    See if you can join NCT04337515 on ClinicalTrials.gov

14. PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

    So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Se…

    Stage

    Phase 1

    Ages

    18 to 70

    Site

    Henry Ford Hospital, Detroit, Michigan

    Run by

    Henry Ford Health System

    See if you can join NCT04886726 on ClinicalTrials.gov

15. Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

    The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM met…

    Stage

    Not phased

    Ages

    3 and older

    Site

    Stanford Hospital, Stanford, California

    Locations

    6 in total

    Run by

    University of Michigan Rogel Cancer Center

    See if you can join NCT05866302 on ClinicalTrials.gov